Key result
GLP-1RA weight reduction tracks with lower CV death and major cardiovascular events, while HbA1c tracks only major cardiovascular events.
Why the study?
GLP-1RAs lower cardiovascular risk in patients with type 2 diabetes, but the mechanism preventing MACE and how metabolic and blood pressure changes relate to cardiovascular event reduction are not fully understood.
How do metabolic and blood pressure changes (HbA1c, weight, systolic blood pressure) induced by GLP-1 receptor agonists relate to reductions in major adverse cardiovascular events and mortality in patients with type 2 diabetes?
Meta-Analysis (n=56,004)
How do metabolic and blood pressure changes (HbA1c, weight, systolic blood pressure) induced by GLP-1 receptor agonists relate to reductions in major adverse cardiovascular events and mortality in patients with type 2 diabetes?
Answers are grounded in this paper and cite their sources.
Cardiovascular and all-cause mortality benefits of GLP-1 receptor agonists are strongly correlated with weight and systolic blood pressure reductions rather than HbA1c lowering, supporting preferential use of agents with greater overall metabolic impact such as liraglutide and semaglutide.
Background Glucagon-like Peptide-1 receptor agonists (GLP-1RAs) have been shown to lower cardiovascular risk, and they are likely to reduce the incidence of all-cause and cardiovascular mortality in patients with type 2 diabetes. In this study-level analysis we investigated how metabolic and blood pressure changes are related to the reduction of cardiovascular events with GLP-1RAs. Methods We included seven randomized, placebo-controlled trials (ELIXA, LEADER, SUSTAIN-6, REWIND, EXSCEL, PIONEER 6, Harmony Outcomes) reporting incidence of one or more of the following outcomes: MACE, stroke, myocardial infarction, cardiovascular death, all-cause death, for a total of 56004 patients. A Pearson correlation analysis between logHR for the occurrence of outcome and placebo-corrected changes in Hb1Ac, systolic blood pressure and weight was performed. Findings Reduction of HbA1c level was significantly related to the reduction of MACE, Pearson R 0.86 (p=0.006) and stroke, Pearson R 0.79 (p=0.018). The reduction of weight instead, showed a robust correlation, not only with reduction of MACE, Pearson R 0.75 (p=0.032) and stroke, Pearson R 0.71 (p=0.047), but also with reduction of both cardiovascular death, Pearson R 0.95 (p=0.003; Picture 1) and all-cause death, Pearson R 0.91 (p=0.013). Reduction of SBP was significantly related to the reduction of both cardiovascular death, Pearson R 0.84 (p=0.036) and all-cause death, Pearson R 0.88 (p=0.020), but not of MACE. Discussion Mechanism of GLP-1RAs in preventing MACE is not fully understood. Other drugs that improve glycemic control did not showed convincing effect on cardiovascular outcome. Our finding prompts some considerations: both weight loss and control of HbA1c levels could play a role in MACE reduction. On the other hand, GLP1-RAs could act through other mechanisms and the metabolic effect could be a marker of the drug potency and dosage. Based on mechanistic studies, a theorized mechanism of cardiovascular benefit seen with GLP-1 RA is thought to be an anti-atherothrombotic and lipid plaque stabilization effect. This seems particularly convincing seeing the strong relationship of weight change and major events reduction. Notably, reduction in cardiovascular mortality and all-cause mortality was not related to the anti-hyperglycemic effect. Contrarily the body weight and SBP reduction were strongly related to both cardiovascular and all-cause mortality. These features could support the presumption of a hypothetic GLP1-RAs mechanism in modulation of lipidic profile and in RAAS inhibition, which have been already proved as beneficial for primary and secondary cardiovascular prevention. Conclusion Cardiovascular protection from GLP1-RAs is not primarily related to HbA1c reduction itself. Our data suggest that GLP-1RAs with the greater metabolic impact, such as liraglutide and semaglutide, should be used to treat diabetic patients to prevent MACE and CV death.
No takes yet. Share an insight, caveat, or question.
Ienno et al. (2021) conducted a meta-analysis in Type 2 diabetes (n=56,004). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) vs. Placebo was evaluated on Correlation between placebo-corrected changes in HbA1c, systolic blood pressure, and weight and logHR for MACE, stroke, myocardial infarction, cardiovascular death, and all-cause death (Pearson R 0.86 (HbA1c and MACE); Pearson R 0.95 (weight and CV death), p=0.006). GLP-1RA-induced reductions in weight correlated with reduced major cardiovascular events and CV death, while HbA1c reduction correlated with major cardiovascular events but not mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: